




PHARMACEUTICAL 2022

Inozyme Pharma Inc.
Rank 155 of 466





PHARMACEUTICAL 2022

Inozyme Pharma Inc.
Rank 155 of 466

The relative strengths and weaknesses of Inozyme Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Inozyme Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Inozyme Pharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 191%, being 113% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	115,342
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,633
Liabilities, Non-Current	2,640
Other Assets	5,816
Other Compr. Net Income	16
Other Expenses	0
Other Liabilities	0
Other Net Income	22
Other Revenues	0
Property and Equipment	2,383
Research and Development	37,720
Selling, General and Administrative Expense	18,926

Output Variable	Value in 1000 USD
Assets	123,541
Liabilities	14,273
Expenses	56,646
Revenues	0
Stockholders Equity	109,268
Net Income	-56,624
Comprehensive Net Income	-56,616
Economic Capital Ratio	191%